Marinomed plans to start a phase IV study of Carragelose nasal spray. The aim is to investigate whether the nasal spray can be used to prevent Covid 19 infections in clinic employees. 334 clinic employees who care for corona patients will take part in the study. Carragelose is believed to reduce the symptoms of a disease.
The study is to be carried out in two clinics in Vienna. Eva Prieschl-Grassauer, CSO at Marinomed, on the background: “This year, our scientists were also able to demonstrate effectiveness against SARS-CoV-2 in cell culture. Carragelose neutralizes the virus and can thereby protect cells from infection. “She continues:” If successful, the study results will show that Carragelose can help in the fight against the pandemic by eliminating the few existing treatment options against the devastating COVID-19 infection extended by an option. “
Christoph Wenisch, head of the infection department in Vienna, adds: “After we have already had positive experiences with carrageenan-based therapies against a wide range of viral respiratory diseases, we are now testing Carragelose as a prophylaxis against COVID-19.”
A phase IV study is a clinical study with a drug that has already been approved.